• Explore /
  • Poster
  • / ENGOT-OV44/FIRST study: a randomized, double-blind, adaptive, phase III study of standard of care (SOC) platinum-based therapy ± dostarlimab followed by niraparib ± dostarlimab maintenance as first-line (1L) treatment of stage 3 or 4 ovarian cancer (OC).

ENGOT-OV44/FIRST study: a randomized, double-blind, adaptive, phase III study of standard of care (SOC) platinum-based therapy ± dostarlimab followed by niraparib ± dostarlimab maintenance as first-line (1L) treatment of stage 3 or 4 ovarian cancer (OC).

Abstract Video & Slides Poster

Authors

null

Anne-Claire Hardy-Bessard

Medical Oncology Department, CARIO-HPCA and Cooperative Gynecological Cancer Research Group (GINECO), Plerin, France

Anne-Claire Hardy-Bessard , Kathleen N. Moore , Mansoor Raza Mirza , Bernard Asselain , Andres Redondo , Jacobus Pfisterer , Sandro Pignata , Diane M. Provencher , David Cibula , Anna K.L. Reyners , Lubomir Bodnar , Rosalind Glasspool , Christos Papadimitriou , Rami Eitan , Sileny N. Han , Linda R. Duska , BJ Rimel , Gupta Divya , Jian Chen , Eric Pujade-Lauraine

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT03602859, EUDRACT 2018-000413-20

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS6101)

DOI

10.1200/JCO.2020.38.15_suppl.TPS6101

Abstract #

TPS6101

Poster Bd #

272

Abstract Disclosures

Similar Posters

First Author: Anne-Claire Hardy-Bessard

First Author: Ignace Vergote

First Author: Myong Cheol Lim

First Author: Leslie M. Randall